Mirum Pharmaceuticals, Inc. (MIRM)
NASDAQ: MIRM · IEX Real-Time Price · USD
39.49
+2.12 (5.67%)
At close: Jul 19, 2024, 4:00 PM
40.10
+0.61 (1.54%)
Pre-market: Jul 22, 2024, 7:43 AM EDT
Mirum Pharmaceuticals Revenue
Mirum Pharmaceuticals had revenue of $224.00M in the twelve months ending March 31, 2024, with 133.90% growth year-over-year. Revenue in the quarter ending March 31, 2024 was $69.22M with 119.07% year-over-year growth. In the year 2023, Mirum Pharmaceuticals had annual revenue of $186.37M with 141.85% growth.
Revenue (ttm)
$224.00M
Revenue Growth
+133.90%
P/S Ratio
8.31
Revenue / Employee
$848,477
Employees
264
Market Cap
1.86B USD
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 186.37M | 109.31M | 141.85% |
Dec 31, 2022 | 77.06M | 57.92M | 302.66% |
Dec 31, 2021 | 19.14M | - | - |
Dec 31, 2020 | 0 | - | - |
Dec 31, 2019 | 0 | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Alignment Healthcare | 2.01B |
National HealthCare | 1.17B |
Warby Parker | 697.80M |
NeoGenomics | 610.66M |
Zai Lab | 291.07M |
LeMaitre Vascular | 199.89M |
RxSight | 101.10M |
MIRM News
- 11 days ago - Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 13 days ago - Mirum Pharmaceuticals' LIVMARLI Approved in the European Union for Patients with PFIC - Business Wire
- 23 days ago - Mirum Submits New Drug Application to FDA for Chenodiol for the Treatment of CTX - Business Wire
- 4 weeks ago - Mirum Pharmaceuticals Highlights Encouraging Data For Rare Liver Disease Therapy From Two Mid-Stage Studies - Benzinga
- 5 weeks ago - Mirum's Volixibat Achieves Positive Interim Analyses in VANTAGE PBC and VISTAS PSC Studies - Business Wire
- 5 weeks ago - Mirum Pharmaceuticals to Host Investor Call to Share Interim Analysis Results from the Volixibat VANTAGE and VISTAS studies on June 17, 2024 - Business Wire
- 6 weeks ago - Mirum Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare Conference - Business Wire
- 7 weeks ago - Mirum Pharmaceuticals Announces Positive CHMP Opinion for LIVMARLI® (maralixibat) Oral Solution for the Treatment of PFIC in Patients Three Months of Age and Older - Business Wire